News
Good News | Wanbangde Pharmaceutical Group Honored by the National Center for Drug Adverse Reaction Monitoring—Upholding Public Health!
Date:
28 Mar,2024
Recently, the Drug Evaluation Center of the National Medical Products Administration and the National Center for Adverse Drug Reaction Monitoring issued the "Notice on Commending National Adverse Drug Reaction Monitoring and Evaluation Units in 2023" (Monitoring & Evaluation Office [2024] No. 14). Among them, Wanbangde Pharmaceutical Group Co., Ltd. has stood out in fulfilling its primary responsibilities and was praised as a representative of pharmaceutical, medical device, and cosmetic enterprises!
Receiving recognition from the National Center for Adverse Drug Reaction Monitoring is not only an acknowledgment of Wanbangde Pharmaceutical Group’s outstanding performance in pharmaceutical safety over the past year, but also clearly demonstrates the company’s professionalism and reliability in this critical area.
Facing this honor, Wanbangde Pharmaceutical Group stated that it will cherish this recognition and turn it into a driving force for future progress. On the journey to ensure pharmaceutical safety, Wanbangde Pharmaceutical Group will continue to uphold the strictest standards, guaranteeing both the quality and safety of its medicines. At the same time, with an even stronger sense of responsibility and mission, the company will enhance its pharmacovigilance capabilities, actively contributing to the development of a robust pharmacovigilance ecosystem—and ultimately delivering new, greater contributions to safeguarding public health.
Related Recommendations